The estimated Net Worth of Theodore R Schroeder is at least $1.96 million dollars as of 28 December 2021. Mr. Schroeder owns over 100,000 units of Nabriva Therapeutics Plc stock worth over $462,748 and over the last 9 years he sold NBRV stock worth over $0. In addition, he makes $1,496,160 as Chief Executive Officer et Director at Nabriva Therapeutics Plc.
Theodore has made over 3 trades of the Nabriva Therapeutics Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 100,000 units of NBRV stock worth $57,000 on 28 December 2021.
The largest trade he's ever made was buying 100,000 units of Nabriva Therapeutics Plc stock on 28 December 2021 worth over $57,000. On average, Theodore trades about 2,105 units every 9 days since 2015. As of 28 December 2021 he still owns at least 325,879 units of Nabriva Therapeutics Plc stock.
You can see the complete history of Mr. Schroeder stock trades at the bottom of the page.
Theodore R. Schroeder serves as Chief Executive Officer, Director of the Company. Prior to the Closing, Mr. Schroeder served as president, chief executive officer and director of Zavante. Previously, Mr. Schroeder co-founded Cadence Pharmaceuticals in 2004 and served as president, chief executive officer and a member of the board of directors until the company’s acquisition by Mallinckrodt Pharmaceuticals in 2014. Prior to that, he held several roles at Elan Pharmaceuticals, including senior vice president of North American sales and marketing, and vice president and general manager of the hospital products business unit, a role he also held at Dura Pharmaceuticals before its acquisition by Elan Pharmaceuticals. Earlier in his career, Schroeder held a number of hospital-related sales and marketing positions with Bristol-Myers Squibb. He currently serves on the public company board of directors of Cidara Therapeutics, Otonomy and Collegium Pharmaceutical. In addition, he previously served on the board of directors of Hyperion Therapeutics, Incline Therapeutics and Trius Therapeutics until their respective acquisitions. Mr. Schroeder is a former chair of BIOCOM, the Southern California life sciences trade association. Mr. Schroeder received a bachelor’s degree in management from Rutgers University.
As the Chief Executive Officer et Director of Nabriva Therapeutics Plc, the total compensation of Theodore Schroeder at Nabriva Therapeutics Plc is $1,496,160. There are 1 executives at Nabriva Therapeutics Plc getting paid more, with Colin Broom having the highest compensation of $2,044,990.
Theodore Schroeder is 65, he's been the Chief Executive Officer et Director of Nabriva Therapeutics Plc since 2018. There are 2 older and 14 younger executives at Nabriva Therapeutics Plc. The oldest executive at Nabriva Therapeutics Plc is George Talbot, 72, who is the Independent member of the Supervisory Board.
Theodore's mailing address filed with the SEC is 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO, CA, 92121.
Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over $3,221,169 worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth $1,215,585 . The most active insiders traders include Capital Viii, Llc Vivo, Bioventures Cayman Ltd Hbm et Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of $23,562. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth $2,155.
nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo
Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include: